Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa...

Area of Science:

• Cardiology
• Interventional Cardiology
• Medical Complications

Background:

• Coronary perforation is a rare but severe complication of percutaneous coronary intervention (PCI).
• Atheroablative technologies and glycoprotein IIb/IIIa inhibitors may influence perforation risk and bleeding complications.
• Understanding risk factors and outcomes is crucial for managing this adverse event.

Purpose of the Study:

• To analyze the incidence and predictors of coronary perforation during PCI.
• To evaluate the association of specific procedural factors and patient history with coronary perforation.
• To determine the relationship between perforation severity and adverse clinical outcomes.

Main Methods:

• Retrospective analysis of 6,214 PCI procedures from January 1995 to June 1999.
• Review of hospital charts and cineangiograms for patients with coronary perforation.
• Statistical analysis to identify associated clinical and procedural factors.

Main Results:

• Coronary perforation occurred in 0.58% of PCIs.
• Higher incidence observed with atheroablative technologies (2.8%) and history of congestive heart failure.
• No association found between abciximab therapy and perforation incidence or classification.
• Class 3 perforations were significantly associated with adverse outcomes like death or emergency surgery.

Conclusions:

• Specific patient demographics and procedural factors are linked to the occurrence and severity of coronary perforation.
• Angiographic classification of perforation is a key determinant of clinical outcomes.
• A proposed algorithm for managing coronary perforation based on its angiographic classification is warranted.